T. Rowe Price Investment Management Inc. Has $1.29 Billion Stock Position in Hologic, Inc. (NASDAQ:HOLX)

T. Rowe Price Investment Management Inc. decreased its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 19.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 17,938,833 shares of the medical equipment provider's stock after selling 4,198,403 shares during the period. Hologic accounts for about 0.8% of T. Rowe Price Investment Management Inc.'s holdings, making the stock its 22nd largest position. T. Rowe Price Investment Management Inc. owned about 7.95% of Hologic worth $1,293,211,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of HOLX. General Partner Inc. acquired a new stake in Hologic in the 4th quarter worth $26,000. Venturi Wealth Management LLC boosted its position in Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after buying an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 260 shares during the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 159 shares during the last quarter. Finally, Smithfield Trust Co increased its stake in shares of Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock valued at $45,000 after buying an additional 400 shares in the last quarter. Institutional investors own 94.73% of the company's stock.

Analysts Set New Price Targets

HOLX has been the subject of several research reports. Leerink Partnrs cut shares of Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Citigroup lowered their price target on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Needham & Company LLC cut shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 price objective for the company. in a research report on Monday, February 3rd. Raymond James reiterated an "outperform" rating and issued a $90.00 price objective (down from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Finally, Stephens restated an "overweight" rating and set a $84.00 target price on shares of Hologic in a research report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $84.62.

Hologic Stock Performance

Shares of Hologic stock opened at $58.19 on Wednesday. The stock's fifty day simple moving average is $61.34 and its 200 day simple moving average is $70.45. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $13.06 billion, a PE ratio of 18.36, a PEG ratio of 2.14 and a beta of 0.82. Hologic, Inc. has a 12 month low of $55.89 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, research analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.